Method for expansion of a population of cells with IL2R beta/common gamma chain antibodies
Anti-CD122 and/or γc antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.
1. A method for expanding a population of cells expressing an IL-2 receptor comprising a complex of CD122 and common γ chain (γc), comprising contacting cells expressing the IL-2 receptor with an antibody or antigen binding fragment which is an IL-2 receptor agonist, and comprises:
(a) an antigen-binding fragment which binds to CD122, comprising:
(i) a light chain variable region comprising the following CDRs:
LC-CDR1:
(SEQ ID NO: 2)
TGTSSDIGHYDFVS,
LC-CDR2:
(SEQ ID NO: 3)
DINNRPS, and
LC-CDR3:
(SEQ ID NO: 4)
SAYTSSDTLV;
and
(ii) a heavy chain variable region comprising the following CDRs:
HC-CDR1:
(SEQ ID NO: 36)
NYYMH,
HC-CDR2:
(SEQ ID NO: 37)
AIMPSRGGTSYPQKFQG, and
HC-CDR3:
(SEQ ID NO: 38)
GEYYYDSSGYYY;
and
(b) an antigen-binding fragment which binds to γc, comprising:
(i) a light chain variable region comprising the following CDRs:
LC-CDR1:
(SEQ ID NO: 68)
RSSQSLLHSNGYNYLD,
LC-CDR2:
(SEQ ID NO: 69)
LGSNRDS, and
LC-CDR3:
(SEQ ID NO: 70)
MQGTHWPWT;
and
(ii) a heavy chain variable region comprising the following CDRs:
HC-CDR1:
(SEQ ID NO: 48)
GYYWS,
HC-CDR2:
(SEQ ID NO: 49)
EINHSGSTNYNPSLKS, and
HC-CDR3:
(SEQ ID NO: 77)
SPGGYSGGYFQH.
2. The method according to claim 1 , wherein the method comprises: culturing cells expressing the IL-2 receptor in the presence of the IL-2 receptor agonist antibody or antigen binding fragment to expand the population of cells expressing the IL-2 receptor; and collecting the expanded population of cells.
3. The method according to claim 2 , wherein the method further comprises:
mixing the expanded population of cells with a pharmaceutically acceptable carrier, adjuvant, excipient or diluent.
4. The method according to claim 1 , wherein the cells expressing the IL-2 receptor comprising a complex of CD122 and γc are obtained from a blood sample from a subject.
5. The method according to claim 1 , wherein the cells expressing the IL-2 receptor are T cells and/or NK cells.
6. The method according to claim 1 , wherein the cells are contacted with the IL-2 receptor agonist antibody or antigen binding fragment in vitro or ex vivo.
7. The method according to claim 1 , wherein the IL-2 receptor agonist antibody or antigen binding fragment is provided in scFv-KiH-Fc or CrossMab format.